Author:
Lane Nancy E.,Corr Maripat
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Eibib, J., Strasser, B. C. & Ross, G. M. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem. Int. 6, 1266–1275 (2012).
2. Schnitzer, T. J. & Marks, J. A. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip and knee. Osteoarthritis Cartilage 23 (Suppl. 1), S8–S17 (2015).
3. Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).
4. Hochberg, M. C. et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).
5. Maloney, J. et al. Efficacy and safety of fasinumab for osteoarthritic pain in patients with moderate to severe osteoarthritis of the knees or hips [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 295 (2016).
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献